D.E. Shaw & Co Portfolio holdings
D. E. Shaw & Co., L.P., founded in 1988 by David E. Shaw, a former Columbia University computer science professor, is a New York City-based global investment management firm renowned for pioneering quantitative investing, managing over $70 billion in assets as of late 2024. Starting with $28 million from Paloma Partners and private investors, the firm employs sophisticated mathematical models and proprietary algorithms—initially developed by a team of scientists and programmers—to exploit market anomalies across public and private markets, including equities, fixed income, and alternatives. Headquartered above a Greenwich Village bookstore in its early days, it now boasts over 2,500 employees across offices in North America, Europe, and Asia, led by a seven-member Executive Committee since Shaw stepped back in 2001 to focus on D. E. Shaw Research. Despite setbacks like the 1998 Russia debt crisis and the 2008 financial downturn, the firm has maintained a reputation for analytical rigor, risk management, and innovation, balancing its computational roots with discretionary strategies.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Tesla
TSLA
|
+$862M |
| 2 |
Baidu
BIDU
|
+$752M |
| 3 |
Tencent Music
TME
|
+$426M |
| 4 |
Coca-Cola
KO
|
+$424M |
| 5 |
NVIDIA
NVDA
|
+$383M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Amazon
AMZN
|
+$981M |
| 2 |
Wells Fargo
WFC
|
+$673M |
| 3 |
Berkshire Hathaway Class B
BRK.B
|
+$574M |
| 4 |
Moderna
MRNA
|
+$442M |
| 5 |
DuPont de Nemours
DD
|
+$415M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 15.93% |
| 2 | Consumer Discretionary | 10.48% |
| 3 | Healthcare | 8.56% |
| 4 | Communication Services | 8.41% |
| 5 | Financials | 6.41% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
OHPAU
2901
DELISTED
Orion Acquisition Corp. Unit
OHPAU
| $1.1M | ﹤0.01% |
+110,558
| New | +$1.11M |
|
2902
UMB Financial
UMBF
$10.8B
| $1.1M | ﹤0.01% |
11,930
-13,655
| -53% | -$1.13M |
|
2903
AptarGroup
ATR
$8.76B
| $1.1M | ﹤0.01% |
7,757
-19,513
| -72% | -$2.69M |
|
2904
PUT
Cardlytics
CDLX
$23M
| $1.1M | ﹤0.01% |
1,000
+510
| +104% | +$673K |
|
2905
CALL
Enbridge
ENB
$121B
| $1.09M | ﹤0.01% |
30,000
| – | – |
|
2906
Navitas Semiconductor
NVTS
$2.5B
| $1.09M | ﹤0.01% |
+109,249
| New | +$1.16M |
|
2907
QCR Holdings
QCRH
$1.68B
| $1.09M | ﹤0.01% |
23,104
+6,224
| +37% | +$267K |
|
|
GLS
2908
DELISTED
Gelesis Holdings, Inc.
GLS
| $1.09M | ﹤0.01% |
+111,652
| New | +$1.14M |
|
2909
Boston Properties
BXP
$11B
| $1.09M | ﹤0.01% |
10,735
-244,289
| -96% | -$23.8M |
|
2910
Camtek
CAMT
$6.5B
| $1.09M | ﹤0.01% |
36,314
+20,780
| +134% | +$557K |
|
2911
VSE Corp
VSEC
$5.51B
| $1.09M | ﹤0.01% |
+27,496
| New | +$1.07M |
|
|
TVRD
2912
CALL
Tvardi Therapeutics
TVRD
$21.7M
| $1.09M | ﹤0.01% |
+1,389
| New | +$951K |
|
2913
Repligen
RGEN
$8.56B
| $1.08M | ﹤0.01% |
5,576
-35,998
| -87% | -$7.38M |
|
|
DHHCU
2914
DELISTED
DiamondHead Holdings Corp. Unit
DHHCU
| $1.08M | ﹤0.01% |
+109,369
| New | +$1.15M |
|
2915
Atlanta Braves Holdings Series A
BATRA
$3.55B
| $1.08M | ﹤0.01% |
37,935
-4,821
| -11% | -$139K |
|
2916
Pulmonx
LUNG
$54.9M
| $1.08M | ﹤0.01% |
+23,636
| New | +$1.36M |
|
|
KE
2917
Kimball Electronics
KE
$588M
| $1.08M | ﹤0.01% |
41,841
-8,339
| -17% | -$190K |
|
2918
Ascendis Pharma A/S
ASND
$16.4B
| $1.08M | ﹤0.01% |
8,367
-14,241
| -63% | -$2.16M |
|
2919
Insteel Industries
IIIN
$628M
| $1.07M | ﹤0.01% |
34,800
-17,748
| -34% | -$529K |
|
2920
Seres Therapeutics
MCRB
$46.4M
| $1.07M | ﹤0.01% |
2,606
-17,144
| -87% | -$7.89M |
|
2921
PUT
Cracker Barrel
CBRL
$1.16B
| $1.07M | ﹤0.01% |
6,200
| – | – |
|
2922
CALL
Goosehead Insurance
GSHD
$1.6B
| $1.07M | ﹤0.01% |
+10,000
| New | +$1.35M |
|
|
USX
2923
DELISTED
U.S. Xpress Enterprises, Inc. Class A Common Stock
USX
| $1.07M | ﹤0.01% |
91,048
-123,978
| -58% | -$1.14M |
|
2924
Corbus Pharmaceuticals
CRBP
$167M
| $1.07M | ﹤0.01% |
18,043
-51,095
| -74% | -$3.36M |
|
2925
SK Telecom
SKM
$11.9B
| $1.07M | ﹤0.01% |
23,782
+10,725
| +82% | +$444K |
|
Similar funds
D.E. Shaw & Co's Q1 2021 Portfolio in Review
As of Q1 2021, D.E. Shaw & Co held 4,712 positions worth $104B, down 7.4% from $112B the previous quarter. Its ten largest holdings account for 9.9% of the portfolio.
D.E. Shaw & Co withdrew a net $18.3B in Q1 2021, closing 730 positions and reducing 1,773 holdings. Its most notable exit was AstraZeneca, an estimated $214M position sold in full.
By sector, the portfolio is most concentrated in Technology at 16% of assets, up from 14% a quarter earlier, followed by Consumer Discretionary and Healthcare.
Against the trend, D.E. Shaw & Co opened a new position in Baidu worth $627M.
- D.E. Shaw & Co's largest Q1 2021 buy was Baidu: 2,881,724 shares worth $627M.
- D.E. Shaw & Co added most to Tesla in Q1 2021, an estimated $862M increase.
- D.E. Shaw & Co's biggest Q1 2021 reduction was Amazon, cutting an estimated $981M.
- D.E. Shaw & Co fully exited AstraZeneca in Q1 2021, selling an estimated $214M.
- D.E. Shaw & Co's ten largest holdings make up 9.9% of its $104B portfolio in Q1 2021.
- D.E. Shaw & Co opened 825 new positions and closed 730 in Q1 2021.
- D.E. Shaw & Co's portfolio value fell 7.4% quarter-over-quarter to $104B.
Based on D.E. Shaw & Co's 13F filing for Q1 2021, filed 17 May 2021.